Celularity Inc. filed a Form 8-K on October 29, 2026, announcing an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs Inc. for U.S.-based peptide active pharmaceutical ingredient production under the Vesalius Peptual brand.

Key Highlights

  • Exclusive collaboration: Celularity entered an exclusive manufacturing and commercial arrangement with Vesalius Longevity Labs Inc. for peptide API work.
  • Scope of services: The collaboration covers U.S.-based purification, processing, analytical testing, and manufacture of peptide active pharmaceutical ingredients under Vesalius's Peptual brand.
  • Facility location: Production is to take place at Celularity's New Jersey facility, according to the filing.
  • Manufacturing standards: The parties intend to operate in accordance with current good manufacturing practice standards, the filing stated.
  • Supply chain goals: The collaboration aims to support consistent product quality, lot-level traceability, and strengthen the resilience and accountability of the peptide API supply chain, per the filing.
  • Signing authority: The report was signed by K. Harold Fletcher, Chief Legal and Strategy Officer of Celularity Inc.

Celularity and Vesalius Longevity Labs Form Exclusive U.S. Peptide API Collaboration

On October 29, 2026, Celularity Inc. (NASDAQ:CELU) reported under Item 8.01 of a Form 8-K that it had issued a press release announcing an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs Inc. The arrangement, according to the filing, is focused on U.S.-based purification, processing, analytical testing, and manufacture of peptide active pharmaceutical ingredients marketed under Vesalius's Peptual registered brand.

The filing describes the collaboration as pairing "Celularity's manufacturing infrastructure and technical expertise with Vesalius's Peptual platform to advance U.S.-based production of peptide APIs in accordance with current good manufacturing practice standards at Celularity's New Jersey facility." Celularity is incorporated in Delaware and maintains its principal executive offices at 170 Park Ave, Florham Park, New Jersey 07932.

According to the filing, the parties intend to establish a domestic supply platform that supports "consistent product quality and lot-level traceability while strengthening the resilience and accountability of the peptide API supply chain." The underlying press release is filed as Exhibit 99.1 to the Current Report and incorporated by reference. The company is identified in the filing as an emerging growth company under applicable Securities Act and Exchange Act definitions.

What Was Disclosed

Celularity filed an 8-K on October 29, 2026, disclosing an exclusive collaboration with Vesalius Longevity Labs Inc. for U.S.-based peptide API manufacturing at Celularity's New Jersey facility under current good manufacturing practice standards.